NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $357 | -71.9% | 508,137 | -9.5% | 0.00% | – |
| Q4 2022 | $1,270 | -99.9% | 561,727 | -13.2% | 0.00% | -100.0% |
| Q3 2022 | $2,072,000 | -17.4% | 647,431 | -1.9% | 0.00% | 0.0% |
| Q2 2022 | $2,509,000 | -4.1% | 660,178 | +43.6% | 0.00% | 0.0% |
| Q1 2022 | $2,616,000 | -58.4% | 459,759 | -1.2% | 0.00% | -50.0% |
| Q4 2021 | $6,284,000 | -28.5% | 465,113 | -5.0% | 0.00% | -33.3% |
| Q3 2021 | $8,794,000 | -0.8% | 489,686 | -5.2% | 0.00% | 0.0% |
| Q2 2021 | $8,867,000 | -14.9% | 516,726 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $10,416,000 | +14.0% | 520,793 | -3.1% | 0.00% | 0.0% |
| Q4 2020 | $9,133,000 | +3.0% | 537,242 | +0.5% | 0.00% | 0.0% |
| Q3 2020 | $8,868,000 | -29.3% | 534,555 | -1.3% | 0.00% | -40.0% |
| Q2 2020 | $12,545,000 | +21.4% | 541,681 | -6.4% | 0.01% | 0.0% |
| Q1 2020 | $10,334,000 | +41.2% | 578,965 | +6.2% | 0.01% | +66.7% |
| Q4 2019 | $7,319,000 | -25.2% | 545,094 | +1.4% | 0.00% | -25.0% |
| Q3 2019 | $9,788,000 | -70.6% | 537,348 | -42.6% | 0.00% | -69.2% |
| Q2 2019 | $33,330,000 | +14083.0% | 936,763 | +24149.6% | 0.01% | +1200.0% |
| Q3 2018 | $235,000 | -91.8% | 3,863 | -85.6% | 0.00% | -94.7% |
| Q1 2018 | $2,853,000 | +527.0% | 26,849 | +252.3% | 0.02% | +533.3% |
| Q4 2017 | $455,000 | -91.9% | 7,622 | -96.7% | 0.00% | -91.9% |
| Q3 2017 | $5,606,000 | -13.8% | 233,572 | -29.8% | 0.04% | -11.9% |
| Q2 2017 | $6,503,000 | +5144.4% | 332,609 | +3190.9% | 0.04% | +4100.0% |
| Q4 2016 | $124,000 | -97.1% | 10,107 | -96.0% | 0.00% | -96.0% |
| Q3 2016 | $4,329,000 | +175.4% | 252,002 | +93.5% | 0.02% | +150.0% |
| Q3 2014 | $1,572,000 | -19.5% | 130,245 | -14.5% | 0.01% | -16.7% |
| Q2 2014 | $1,952,000 | +4.1% | 152,248 | -1.7% | 0.01% | +9.1% |
| Q1 2014 | $1,876,000 | +139.9% | 154,813 | +124.6% | 0.01% | +120.0% |
| Q4 2013 | $782,000 | -8.9% | 68,941 | -16.1% | 0.01% | -16.7% |
| Q3 2013 | $858,000 | – | 82,173 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |